Fig. 2: Local reactions and systemic events reported within 7 days after administration of BNT162b2 or placebo in participants 20–64 years of age and 65–85 years of age.

A, B Local reactions after doses 1 and 2, respectively. C, D Systemic events after doses 1 and 2, respectively. Results are for the safety population (20–64 years of age: n = 97 for BNT162b2, and n = 33 for placebo; 65–85 years of age: n = 22 for BNT162b2, and n = 8 for placebo). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity), or grade 4 (led to emergency department visit or hospitalization). Redness and swelling were graded as mild (>2.0–5.0 cm in diameter), moderate (>5.0–10.0 cm in diameter), severe (>10.0 cm in diameter), or grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Fever categories are shown in the key. Fatigue, headache, chills, and new or worsened muscle or joint pain were graded as mild (does not interfere with activity), moderate (some interference with activity), or severe (prevents daily activity). Vomiting was graded as mild (1–2 times in 24 h), moderate (>2 times in 24 h), or severe (requires intravenous hydration), and diarrhea as mild (2–3 loose stools in 24 h), moderate (4–5 loose stools in 24 h) or severe (≥6 loose stools in 24 h). Grade 4 for all systemic events indicated an emergency department visit or hospitalization. No participant experienced a grade 4 local reaction or systemic event. Data are presented as percentages with associated 95% CIs shown as error bars for the percentage of participants experiencing any reaction.